INmune Bio Inc. filed a Form S-1 registration statement with the SEC on November 20, 2026, covering the resale of up to 3,000,000 shares of common stock issuable upon exercise of a Common Warrant issued in an October 2026 private placement.
Key Highlights
- Shares registered: Up to 3,000,000 shares of common stock, par value $0.001 per share, issuable upon exercise of a Common Warrant.
- Source of shares: The Common Warrant was issued in a private placement under a Securities Purchase Agreement dated October 27, 2026.
- Selling stockholder only: INmune Bio is not selling any shares under this prospectus and will not receive any proceeds from the resale.
- Last reported share price: On November 19, 2026, the last reported sale price of INmune Bio common stock on the Nasdaq Capital Market was $0.8941 per share.
- Company classification: The registrant identified itself as a non-accelerated filer and a smaller reporting company.
- Expense allocation: The company will pay all registration expenses other than discounts, concessions, commissions, and similar selling expenses, which are borne by the selling stockholder.
INmune Bio Registers Warrant Shares from October 2026 Private Placement
According to the filing, INmune Bio Inc. (NASDAQ:INMB), a Nevada-incorporated biopharmaceutical company headquartered at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432, submitted a preliminary Form S-1 registration statement on November 20, 2026. The registration covers the potential resale of up to 3,000,000 shares of common stock by a single selling stockholder named in the prospectus. Those shares are issuable upon exercise of a Common Warrant that INmune Bio issued as part of a private placement governed by a Securities Purchase Agreement dated October 27, 2026.
The filing states that INmune Bio is not offering or selling any shares under this prospectus and will not receive any of the proceeds from the selling stockholder's resale of the Warrant Shares. The selling stockholder may offer the shares "from time to time" and through various methods described in the prospectus's "Plan of Distribution" section, at varying prices. All discounts, concessions, commissions, and similar selling expenses related to those sales are to be borne by the selling stockholder, while the company has agreed to pay other registration-related costs.
The filing notes that investing in INmune Bio's securities "involves a high degree of risk" and directs prospective investors to the "Risk Factors" section beginning on page 4. The prospectus is preliminary and subject to completion; the selling stockholder may not sell the registered shares until the registration statement becomes effective. The company's common stock is listed on the Nasdaq Capital Market under the symbol "INMB," with a last reported sale price of $0.8941 per share on November 19, 2026, according to the filing.
What Was Disclosed
INmune Bio filed a preliminary S-1 on November 20, 2026, to register up to 3,000,000 common shares for resale by a selling stockholder holding a Common Warrant from an October 27, 2026 private placement. The company will receive no proceeds from these sales.




Please wait processing your request...